If you missed the live webinar, don’t worry — the full recording is available below.   https://www.youtube.com/watch?v=qM9b0n2_L0c&t=1226s   In this session, we introduce SILCS v2026, including several new capabilities and workflow enhancements designed to improve interpretability, efficiency, and decision‑making in computational drug discovery. This update may be particularly relevant for those working on lead [...]

April 21, 2026, Baltimore, MD – SilcsBio, a technology company that develops and markets software and services for structure-based drug design, is excited to announce the hiring of Ashlin Poruthoor, Ph.D. as Applications Scientist. Ashlin has been a post-doctoral fellow with Prof. Alexander MacKerell at the University of Maryland Baltimore investigating novel fingerprints for ML-AI [...]

Targeting transcription factors that act as master regulators of cancer progression has long been an important goal in oncology drug discovery. Among the most prominent of these are hypoxia-inducible factors 1 and 2 (HIF‑1 and HIF‑2), which orchestrate broad transcriptional programs that drive tumor growth, angiogenesis, metastasis, and immune evasion. Despite their importance, effectively targeting [...]

Beyond Binding – Fast, Scalable koff Predictions Powered by SILCS and AI SilcsBio hosted a webinar on January 15th, 2026 showcasing how SILCS‑Kinetics is transforming the study of ligand binding–unbinding kinetics by enabling rapid, scalable predictions of ligand dissociation rates (koff) using a combination of physics‑based modeling and machine learning.   About SILCS‑Kinetics Understanding ligand [...]